
Proteogenix는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
제품 번호
PX-TA1750
제품 특징
Product name | Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade |
---|
Source | CAS 2578319-11-4 |
---|
Species | Homo sapiens |
---|
Expression system | XtenCHO |
---|
Molecular weight | 143.8kDa |
---|
Purity | >85% |
---|
Buffer | PBS buffer PH7.5 |
---|
Delivery condition | Blue ice (+4°C) |
---|
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
---|
Delivery Time | 3-5 days if in stock; 3 week if production needed |
---|
Storage condition | store at -80°C |
---|
Brand | ProteoGenix |
---|
Aliases /Synonyms | Bebtelovimab,LY-CoV1404, LY3853113,SARS-CoV-2 Spike Protein,anti-SARS-CoV-2 Spike Protein |
---|
Reference | PX-TA1750 |
---|
Note | For research use only. Not suitable for human use. |
---|
Isotype | IgG1,kappa |
---|
Clonality | Monoclonal Antibody |
---|
QC & Validation Data
SDS-PAGE for Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb
Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Publications
- - Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
- - Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
- - Melissa García-Vega, Edgar A. Melgoza-González, Sofía Hernández-Valenzuela, Harold Marcotte, Qiang Pan-Hammarström, Jesús Hernández et al., 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern, iScience, Volume 26, ISSUE 4, 106562, April 21, 2023, https://doi.org/10.1016/j.isci.2023.106562
- - Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168
ProteoGenix의 모든 제품들을 만나보세요!
Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"